Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces its Submission of a New Drug Application for TREAKISYM® Ready-To-Dilute Formulation
Eagle Pharmaceuticals, Inc. (Eagle or the Company) (NASDAQ: EGRX) today announced that its marketing partner SymBio Pharmaceuticals Limited (SymBio) has submitted a New Drug Application (NDA) for TREAKISYM ready-to-dilute (RTD) liquid formulation in Japan.
- Eagle Pharmaceuticals, Inc. (Eagle or the Company) (NASDAQ: EGRX) today announced that its marketing partner SymBio Pharmaceuticals Limited (SymBio) has submitted a New Drug Application (NDA) for TREAKISYM ready-to-dilute (RTD) liquid formulation in Japan.
- SymBio expects to launch the TREAKISYM RTD product in the first quarter of 2021, after obtaining marketing authorization.
- In September 2017, Eagle licensed to SymBio intellectual property necessary to develop, market and sell RTD and rapid infusion (RI) formulations of TREAKISYM in Japan.
- According to SymBio, sales in Japan for TREAKISYM were $78 million in 2018 and $77 million through June 30, 2019.